key: cord-0903552-5lyxk9om
authors: Kim, Ji-Won; Yoon, Jun Sik; Kim, Eun Jin; Hong, Hyo-Lim; Kwon, Hyun Hee; Jung, Chi Young; Kim, Kyung Chan; Sung, Yu Sub; Park, Sung-Hoon; Kim, Seong-Kyu; Choe, Jung-Yoon
title: Prognostic Implication of Baseline Sarcopenia for Length of Hospital Stay and Survival in Patients with Coronavirus Disease 2019
date: 2021-03-29
journal: J Gerontol A Biol Sci Med Sci
DOI: 10.1093/gerona/glab085
sha: 49047be1c87bb7abea3ba0f7da93dfd6e744410f
doc_id: 903552
cord_uid: 5lyxk9om

BACKGROUND: The impact of sarcopenia on clinical outcomes of coronavirus disease 2019 (COVID-19) is not clearly determined yet. We aimed to investigate the association between baseline sarcopenia and clinical outcomes in patients with COVID-19. METHODS: All hospitalized adult patients with COVID-19 who had baseline chest computed tomography (CT) scans at a Korean university hospital from February 2020 to May 2020 were included. The main outcome was time from hospital admission to discharge. Death was considered as a competing risk for discharge. Baseline skeletal muscle cross-sectional area at the level of the 12th thoracic vertebra was measured from chest CT scans. The lowest quartile of skeletal muscle index (skeletal muscle cross-sectional area divided by height-squared) was defined as sarcopenia. RESULTS: Of 121 patients (median age, 62 years; 44 men; 29 sarcopenic), 7 patients died and 86 patients were discharged during the 60-day follow-up. Patients with sarcopenia showed a longer time to discharge (median, 55 vs. 28 days; p<0.001) and a higher incidence of death (17.2% vs. 2.2%; p=0.004) than those without sarcopenia. Baseline sarcopenia was an independent predictor of delayed hospital discharge (adjusted hazard ratio [aHR], 0.47; 95% CI, 0.23-0.96), but was not independently associated with mortality in patients with COVID-19 (aHR, 3.80; 95% CI, 0.48-30.26). The association between baseline sarcopenia and delayed hospital discharge was consistent in subgroups stratified by age, sex, comorbidities, and severity of COVID-19. CONCLUSION: Baseline sarcopenia was independently associated with prolonged hospital stay in patients with COVID-19. Sarcopenia could be a prognostic marker in COVID-19.

In the absence of specific treatments for coronavirus disease 2019 , the COVID-19 pandemic has become a tremendous threat to human health worldwide. Most patients with COVID-19 experience mild to moderate disease, but some patients can develop severe respiratory illness and finally death. Older age, chronic comorbid conditions, and higher concentrations of d-dimer, interleukin-6, or C-reactive protein have all been associated with higher mortality in COVID-19 (1) (2) (3) (4) (5) (6) . However, factors associated with prolonged hospitalization in survivors of COVID-19 are not fully investigated. Because prolonged hospital stay increases the burden to public health under limited hospital resources, identifying these factors would be useful.

Sarcopenia is a muscle disorder characterized by low muscle strength combined with low muscle quantity or quality (7) . Sarcopenia is highly associated with aging, but illness, malnutrition, and physical inactivity can also contribute to the development of sarcopenia (7) .

The adverse health effects of sarcopenia include poor quality of life, disability, and increased risk of falls, fractures, and hospitalization (8) (9) (10) . In addition, the presence of sarcopenia is a proven predictor of treatment outcomes in patients with acute or chronic illness and those undergoing surgery (11) (12) (13) (14) (15) (16) . On computed tomography (CT), sarcopenia defined by the muscle mass at the level of the 3 rd lumbar vertebra (L3) has predicted survival in patients with hepatocellular carcinoma and in liver transplant recipients (11, 12) . CT-defined sarcopenia also predicted survival and length of intensive care unit (ICU) stay in patients requiring ICU admission after traumatic injuries (13) .

CT is a useful tool for identifying sarcopenia by measuring muscle area in crosssectional images, most commonly at the L3 level, which well represents the total body skeletal muscle mass (17, 18) . The skeletal muscle mass can also be measured at the level of A c c e p t e d M a n u s c r i p t 4 the 12 th thoracic vertebra (T12), which is highly correlated with the skeletal muscle mass at L3 and can also reflect clinical outcomes (19) .

The association between sarcopenia and treatment outcomes in COVID-19 has not been examined. Therefore, we investigated the association between baseline sarcopenia and length of hospital stay and survival in hospitalized patients with COVID-19 by assessing for baseline sarcopenia using chest CT scans that were initially performed to evaluate COVID-19 pneumonia.

All patients with COVID-19 who were hospitalized at Daegu Catholic University Medical Center from February 17 to May 19, 2020 and had chest CT scans at baseline were eligible for this retrospective cohort study. Patients who did not have CT scans at baseline and those younger than 19 years were excluded from the study. The diagnosis of COVID-19 was based on positive real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV-2 RNA in nasopharyngeal and oropharyngeal swab specimens. The study was approved by the Institutional Review Board of Daegu Catholic University Medical Center (CR-20-110). Informed consent was waived because of the retrospective study design.

Cross-sectional images were obtained from chest CT scans that were performed for evaluation of COVID-19 pneumonia at the time of admission. Cross-sectional areas of muscle and fat were measured from the axial CT image nearest to the inferior border of the T12 vertebral body by using AsanJ-Morphometry software (Seoul, South Korea), including erector spinae, external and internal oblique, latissimus dorsi, rectus abdominis, and external A c c e p t e d M a n u s c r i p t 5 and internal intercostal muscles. Tissue Hounsfield Unit (HU) thresholds were 0 to 100 HU for skeletal muscle and -190 to -30 HU for subcutaneous and visceral fat tissues. Total muscle area (cm 2 ) was determined after excluding the total intramuscular fat area (total intramuscular fat area = total fat areasubcutaneous fat areavisceral fat area; Figure 1 ).

The skeletal muscle index (cm 2 /m 2 ) was calculated as total muscle area adjusted for height.

Sarcopenia was defined as the lowest quartile of skeletal muscle index, which was ≤24 cm 2 /m 2 for men and ≤20 cm 2 /m 2 for women. The reference values for sarcopenia were ≤29 

Main outcome was time from hospital admission to discharge. Time to reaching study endpoint (discharge or death) was assessed until 60 days after admission. COVID-19 patients discharged alive are those who meet the criteria of 1) negative conversion of SARS-CoV-2 RNA from nasopharyngeal and oropharyngeal swabs (detection of two consecutive negative RT-PCR results), and 2) improvement of clinical symptoms and vital signs and/or resolution A c c e p t e d M a n u s c r i p t 6 of pneumonia. Most people who discharged met both the PCR-negative and clinical criteria for discharge within a week apart.

Data on age, sex, comorbidities (diabetes, hypertension, cardiovascular disease, chronic lung disease, and chronic kidney disease), duration of symptoms before admission, symptoms (cough, sputum, fever, dyspnea, diarrhea, etc.), oxygen support, chest CT findings, and laboratory values at baseline were obtained from the medical records. National Early Warning Score 2 (NEWS2, range 0 to 20) was determined from respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness or new confusion, and temperature at baseline (20) . A higher score indicates greater clinical risk, with 0 to 4 = low risk; 5 to 6 = medium risk; and 7 or more = high risk. Data on treatment with antibiotics, glucocorticoids, or IV immunoglobulin, use of nasal prong, high-flow nasal cannula, or mechanical ventilation, and complications such as acute respiratory distress syndrome (ARDS) and shock were also collected retrospectively. ARDS was defined using the Berlin definition (21) and shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock (22).

Comparison of two groups was conducted using Mann-Whitney U test for continuous variables and Chi-Square test or Fisher's exact test for categorical variables. We executed a competing risk model for discharge outcome. Death was considered as a competing risk for discharge. Patients still hospitalized 60 days after admission and those who were transferred before study endpoint were censored. Cumulative incidence plots for discharge (or death) between patients with and without sarcopenia were drawn and compared by using Gray's test.

A c c e p t e d M a n u s c r i p t 7 The association between baseline sarcopenia and hospital discharge was investigated using a Fine and Gray proportional subdistribution hazards regression model. Subgroup analyses stratified by age, sex, comorbidities, disease severity, and treatment were also performed to estimate the predictive performance of sarcopenia on hospital discharge. All statistical analyses were performed using R software, version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria).

Total 121 patients were included in this study after excluding 7 patients who did not have chest CT scans at baseline and 2 patients who were under the age of 19 (Figure 2) .

Characteristics of the patients are described in Table 1 Patients with sarcopenia presented with more severe disease at baseline, as indicated by higher NEWS2, more frequent oxygen support, and higher C-reactive protein (CRP) levels, than those without sarcopenia ( Table 1) . Sarcopenic individuals were older and had more frequent prevalence of hypertension and cardiovascular disease than those who were not sarcopenic. However, the duration of symptoms before admission and the presence of Sarcopenia was more common in patients with prolonged hospital stay than in patients without prolonged hospital stay (28.8% vs. 12.7%; p = 0.035).

To determine whether baseline sarcopenia could predict the length of hospital stay, cumulative incidence curves for discharge or death were depicted separately in patients with and without sarcopenia (Figure 3 ). Patients with sarcopenia had significantly longer hospital stay than those without sarcopenia (median, 55 vs. 28 days; Gray's test, p <0.001). In addition, patients with sarcopenia had a significantly higher death rate than those without sarcopenia (17.2% vs. 2.2%; Gray's test, p = 0.004).

Next, Fine and Gray proportional subdistribution hazards regression model for competing risks was performed to determine whether baseline sarcopenia had an independent effect on predicting length of hospital stay in patients with COVID-19 ( addition, baseline sarcopenia tended to be associated with high mortality in patients with COVID-19, but without statistical significance (aHR, 3.80; 95% CI, 0.48-30.26). We then conducted additional analyses to determine whether sarcopenia was a consistent predictor of length of hospital stay in different subgroups (Supplementary Figure S1) . Patients with sarcopenia at baseline were likely to experience delayed hospital discharge consistently in subgroups according to age, sex, comorbidities, disease severity, and steroid treatment.

For sensitivity analysis, we investigated the association between sarcopenia and length of hospital stay only in survivors of COVID-19 (excluding 7 non-survivors). Sarcopenia was an independent predictor of delayed hospital discharge after adjusting for age, sex, diabetes, hypertension, cardiovascular disease, chronic lung disease, oxygen support at baseline, and CRP levels at baseline (aHR, 0.60; 95% CI, 0.37-0.96), which was in line with the results from the primary analysis.

The main question of this study was whether baseline sarcopenia was associated with the prognosis of COVID-19 in terms of length of hospital stay and survival. We used chest CT scans, which were performed to evaluate the presence and severity of pneumonia, to determine the presence of sarcopenia at baseline. Sarcopenia was an independent predictor of prolonged hospital stay in patients with COVID-19. The impact of sarcopenia on length of hospital stay was consistently observed in subgroups with regards to age, sex, comorbidities, and severity of COVID-19. In addition, sarcopenia tended to be associated with high The association between sarcopenia and adverse outcomes of COVID-19 has been supported by other studies that examined CT-defined sarcopenia or clinical frailty scores in patients with COVID-19 (29-31). Low pectoralis muscle index (obtained by measuring the area of the pectoralis muscle on axial chest CT images) in patients with COVID-19 was associated with prolonged hospital stay and death (29). In a multi-center study in Europe, higher frailty scores in patients with COVID-19 were linked to higher mortality risk and longer duration of hospital stay compared with lower frailty scores (30). The presence of A c c e p t e d M a n u s c r i p t 11 diabetes, hypertension, and coronary artery disease was not associated with mortality or duration of hospital stay, indicating that frailty is a better predictor of the clinical course of COVID-19 than comorbidities (30). Our results, along with those of the other studies, suggest that evaluating muscle area on chest CT can be a simple and useful tool for predicting outcomes in patients with COVID-19.

Sarcopenia might also explain the heterogeneity of disease course in the context of aging. Generally, increasing age is considered to be a prognostic factor in multiple diseases.

However, individually, age alone may have variable and inconsistent effects in predicting clinical outcomes (32). Being old does not always mean being unhealthy, and conversely, younger people may experience poor health-related outcomes (32). Sarcopenia, as well as frailty, might be a latent prognostic factor which partially accounts for the heterogeneity of associations between age and clinical outcomes (33). The clinical course of COVID-19 in older patients with the disease differs according to their frailty status. Frail patients have a higher mortality risk and experience severe disease more frequently than non-frail patients (31, 34). Our study found that sarcopenia was a reliable marker of prolonged hospital stay in a subgroup of older patients with COVID-19, confirming that not all older people have similar outcomes in COVID-19. Sarcopenia and frailty also predict mortality in patients with various other medial or surgical conditions, regardless of age (14, (35) (36) (37) . Sarcopenia, which reflects body composition better than body mass index, is a key physical component of frailty (38) . The present study demonstrated that baseline sarcopenia serves as a predictor of adverse outcomes in COVID-19 independently of age.

There are some limitations of this study. First, our study was conducted within a retrospective design. Further large, prospective study would be required to support our findings. Second, sarcopenia was defined based on only muscle mass in our study, while the A c c e p t e d M a n u s c r i p t 12 current definition of sarcopenia is based on muscle mass and function (7) . Third, reference values for sarcopenia measured from CT scans at thoracic levels are not determined in Korean population. However, cutoffs for height-adjusted cross-sectional area (skeletal muscle index) measured at the T12 level in our study population were quite similar to those in a healthy group in the United States (39). Fourth, we could not measure the skeletal muscle index at L3 across the study group because most of the patients had only chest CT scans.

Instead, we checked the correlation between skeletal muscle indices from T12 and L3 levels in patients who had both chest and abdominal CT scans (n=15) and found a close relationship between them. Fifth, length of hospital stay might be influenced by several external factors such as social support, living environment, and services. However, we set the criteria for discharge in case of patients with COVID-19 (aforementioned in the methods section), and most patients followed these criteria. To overcome this possible limitation, mortality risk, as well as length of hospital stay, was evaluated in our study, because both mortality and hospital discharge are commonly selected outcomes in clinical studies of COVID-19 (3, 29, 30).

In conclusion, baseline sarcopenia was independently associated with duration of hospital stay in hospitalized patients with COVID-19. Patients with sarcopenia had increased mortality, but the association was not statistically significant. Although chest CT was originally conducted to evaluate the presence and severity of pneumonia in patients with COVID-19, it provided an additional value to assess for sarcopenia, which is a prognostic marker of COVID-19. 

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Sarcopenia: revised European consensus on definition and diagnosis

Validation of the SarQoL®, a specific healthrelated quality of life questionnaire for Sarcopenia

The Predictive Value of the EWGSOP Definition of Sarcopenia: Results From the InCHIANTI Study

Sarcopenic Obesity and Its Temporal

Associations With Changes in Bone Mineral Density, Incident Falls, and Fractures in Older Men: The Concord Health and Ageing in Men Project

intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma

Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score

Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer

Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review

Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review

What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults?

Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image

Diagnosing Sarcopenia on

Thoracic Computed Tomography: Quantitative Assessment of Skeletal Muscle Mass in Patients Undergoing Transcatheter Aortic Valve Replacement

Royal College of Physicians. National Early Warning Score (NEWS) 2

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Skeletal muscle as potential central link between sarcopenia and immune senescence

Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer

Laboratory values at baseline, median (IQR)

White blood cell count

Lymphocyte count